Rapport Therapeutics Inc. added $20 million to its cash runway for its lead phase III oral seizure drug, RAP-219, through a potential $328 million license deal signed with Tenacia Biotechnology Co. Ltd.
We use necessary cookies to make our site work. If you allow, we use optional cookies to measure our site’s performance, personalize content and ads to you, and provide social media features.Learn more
Cookie Preference Center
Cookie Preference Center
Your preferences
Strictly Necessary Cookies
Functional Cookies
Targeting Cookies
Performance Cookies
Your preferences
As described in our Corporate Privacy Notice and Cookie Policy, we use cookies (including pixels or other similar technologies) on our websites, mobile applications and related products (the “services”). The types of cookies we use are described below.
Strictly Necessary Cookies
Always Active
These are cookies necessary for the services to function and are always active. They are usually only set in response to actions made by the user which amount to a request for services, such as setting privacy preferences, logging in, or filling in forms.
Functional Cookies
These cookies enable the services to provide enhanced functionality and personalization. They may be set by us or by third party providers we use to provide the services. If you do not allow these cookies to run, then the services may not function properly.
Targeting Cookies
These cookies may be set through the services by our advertising partners to learn about your interests and present you with relevant advertisements on other sites. These advertising partners may be able to identify you based on your device or other online activity.
Performance Cookies
These cookies count visits and traffic sources in order to measure and improve the performance of the services. They help identify which pages or functions within the services are the most and least popular and see how visitors move around our services.
